This content may be outdated
This article was published more than 1 year ago. While we strive to keep our content up to date, medical coding guidelines and regulations may have changed since then.
Below is a list summarizing the CPT codes for multianalyte assays with algorithmic analyses.
CPT Code 81490
CPT 81490 describes the analysis of 12 biomarkers using immunoassays, utilizing serum, for autoimmune (rheumatoid arthritis) with a prognostic algorithm reported as a disease activity score.
CPT Code 81493
CPT 81493 describes a risk score algorithm reported as the result of gene expression profiling by real-time RT-PCR of 23 genes utilizing whole peripheral blood to diagnose coronary artery disease.
CPT Code 81500
CPT 81500 describes a biochemical assay of two proteins (CA-125 and HE4) utilizing serum, with menopausal status, algorithm reported as a risk score for oncology (ovarian).
CPT Code 81503
CPT 81503 describes an algorithm reported as a risk score utilizing serum biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin) for oncology (ovarian).
CPT Code 81504
CPT 81504 describes oncology microarray gene expression profiling of more than 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, with results reported as tissue similarity scores.
CPT Code 81506
CPT 81506 describes endocrinology (type 2 diabetes) biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha) utilizing serum or plasma, with an algorithm reporting a risk score.
CPT Code 81507
CPT 81507 describes DNA sequence analysis of selected regions using maternal plasma, an algorithm reported as a risk score for each trisomy of fetal aneuploidy (trisomy 21, 18, and 13).
CPT Code 81508
CPT 81508 describes the utilization of maternal serum to perform biochemical assays of two proteins (PAPP-A, hCG [any form]) to assess congenital fetal abnormalities, with an algorithm reported as a risk score.
CPT Code 81509
CPT 81509 describes a risk score algorithm utilizing maternal serum for congenital fetal abnormalities based on biochemical assays of three proteins (PAPP-A, hCG [any form], DIA).
CPT Code 81510
CPT 81510 describes a risk score algorithm that utilized maternal serum for congenital fetal abnormalities, with biochemical assays of three analytes (AFP, uE3, hCG [any form]).
CPT Code 81511
CPT 81511 describes a maternal serum algorithm reported as a risk score for congenital fetal abnormalities, utilizing biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) and may include additional results from previous biochemical testing.
CPT Code 81512
CPT 81512 describes a risk score algorithm that utilizes maternal serum for congenital fetal abnormalities, with biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA).
CPT Code 81513
CPT 81513 describes quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, with an algorithm reported as a positive or negative result for bacterial vaginosis, to diagnose infectious disease, bacterial vaginosis.
CPT Code 81514
CPT 81514 describes a quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii) utilizing vaginal-fluid specimens, with an algorithm reported as a positive or negative for a high likelihood of bacterial vaginosis. In addition, they included separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, and Candida krusei when reported.
CPT Code 81518
CPT 81518 describes using formalin-fixed paraffin-embedded tissue to perform real-time RT-PCR gene expression profiling of 11 genes (7 content and four housekeeping) in oncology (breast), with algorithms reported as percentage risk for metastatic recurrence and the likelihood of benefit from extended endocrine therapy.
CPT Code 81519
CPT 81519 describes an algorithm reported as a recurrence score obtained through real-time RT-PCR of 21 genes in formalin-fixed paraffin-embedded tissue from an oncology (breast) setting.
CPT Code 81520
CPT 81520 describes a procedure of oncology (breast) mRNA gene expression profiling by hybrid capture of 58 genes (50 content and eight housekeeping) utilizing formalin-fixed paraffin-embedded tissue, with the algorithm reported as a recurrence risk score.
CPT Code 81521
CPT 81521 describes oncology (breast) mRNA microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, with an algorithm reported as an index related to the risk of distant metastasis.
CPT Code 81522
CPT 81522 describes a procedure for oncology (breast) mRNA gene expression profiling by RT-PCR of 12 genes (8 content and four housekeeping) utilizing formalin-fixed paraffin-embedded tissue, with an algorithm reported as a recurrence risk score.
CPT Code 81523
CPT 81523 describes next-generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes utilizing formalin-fixed paraffin-embedded tissue from an oncology (breast) setting, with an algorithm reported as an index related to the risk of distant metastasis.
CPT Code 81525
CPT 81525 describes a recurrence score algorithm reported from real-time RT-PCR of 12 genes (7 content and five housekeeping) utilizing formalin-fixed paraffin-embedded tissue in an oncology (colon) gene expression profiling.
CPT Code 81528
CPT 81528 describes a quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result for oncology (colorectal) screening.
CPT Code 81529
CPT 81529 describes a procedure for oncology (cutaneous melanoma) that involves mRNA gene expression profiling by real-time RT-PCR of 31 genes (28 content and three housekeeping) utilizing formalin-fixed paraffin-embedded tissue, with an algorithm reported as recurrence risk, including the likelihood of sentinel lymph node metastasis.
CPT Code 81535
CPT 81535 describes oncology (gynecologic) live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, with a predictive algorithm reported as a drug response score for the first single drug or drug combination.
CPT Code 81538
CPT 81538 describes a mass spectrometric 8-protein signature utilizing serum, including amyloid A, for oncology (lung) with a prognostic and predictive algorithm reported as good versus poor overall survival.
CPT Code 81539
CPT 81539 describes a prognostic algorithm reported as a probability score utilizing plasma or serum for an oncology biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]) for high-grade prostate cancer.
CPT Code 81540
CPT 81540 describes a procedure utilizing formalin-fixed paraffin-embedded tissue to perform real-time RT-PCR gene expression profiling of 92 genes (87 content and five housekeeping) to classify an oncology tumor of unknown origin into its main cancer type and subtype, with an algorithm reported as a probability of a predicted main cancer type and subtype.
CPT Code 81541
CPT 81541 describes a procedure for oncology (prostate) utilizing formalin-fixed paraffin-embedded tissue, which involves mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), and the algorithm reported as a disease-specific mortality risk score.
CPT Code 81542
CPT 81542 describes a microarray gene expression profiling of 22 content genes utilizing formalin-fixed paraffin-embedded tissue, with an algorithm reported as a metastasis risk score for oncology (prostate).
CPT Code 81546
CPT 81546 describes an oncology (thyroid) mRNA gene expression analysis of 10,196 genes, utilizing fine needle aspirate, with an algorithm reported as a categorical result (e.g., benign or suspicious).
CPT Code 81551
CPT 81551 describes a procedure for utilizing formalin-fixed paraffin-embedded tissue to perform real-time PCR of three genes (GSTP1, APC, RASSF1) for promoter methylation profiling in oncology (prostate), with an algorithm reported as a likelihood of prostate cancer detection on repeat biopsy.
CPT Code 81552
CPT 81552 describes the algorithm reported as the risk of metastasis for oncology (uveal melanoma) mRNA gene expression profiling by real-time RT-PCR of 15 genes (12 content and three housekeeping) utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue.
CPT Code 81554
CPT 81554 describes mRNA gene expression analysis of 190 genes utilizing transbronchial biopsies to diagnose idiopathic pulmonary fibrosis (IPF) with a diagnostic algorithm reported as a categorical result (e.g., positive or negative for a high probability of usual interstitial pneumonia [UIP]).
CPT Code 81560
CPT 81560 describes the measurement of donor and third-party-induced CD154+T-cytotoxic memory cells utilizing whole peripheral blood, with an algorithm reported as a rejection risk score for transplantation medicine (allograft rejection, pediatric liver, and small bowel).
CPT Code 81595
CPT 81595 describes the utilization of subfraction of peripheral blood for cardiology (heart transplant) mRNA gene expression profiling by real-time quantitative PCR of 20 genes (11 content and nine housekeeping), with an algorithm reported as a rejection risk score.
CPT Code 81596
CPT 81596 describes the utilization of six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum to diagnose chronic hepatitis C virus (HCV) infection and report prognostic algorithm scores for fibrosis and necroinflammatory activity in the liver.
CPT Code 81599
CPT 81599 describes an unlisted multianalyte assay with algorithmic analysis.
This content may be outdated
This article was published more than 1 year ago. While we strive to keep our content up to date, medical coding guidelines and regulations may have changed since then.
